This page shows the latest vedolizumab news and features for those working in and with pharma, biotech and healthcare.
Takeda has high hopes for ixazomib, billing it as the company's second 'global launch' after ulcerative colitis therapy Entyvio (vedolizumab) - in other words a product that it will launch not
NICE has recommended Entyvio (vedolizumab) to treat moderate to severe ulcerative colitis in final draft guidance. ... Vedolizumab works in a different way to other treatment options [by] targeting the immune system in the gut rather than the whole body
Professor Carole Longson, director of NICE's health technology evaluation centre, said: “ Unfortunately the maker of vedolizumab did not give the committee enough information to show how well it worked when
These include the recently-approved Entyvio (vedolizumab) for Crohn's disease and ulcerative colitis, ixazomib (MLN9708) for multiple myeloma and alisertib (MLN8237) for peripheral T cell lymphoma.
However, the company's Entyvio (vedolizumab) has received approvals this year in both the EU and US for use in Crohn's disease and ulcerative colitis.
The European Commission (EC) has approved Takeda's Entyvio (vedolizumab) to treat adults with ulcerative colitis and Crohn's disease and Boehringer Ingelheim/Lilly's Jardiance (empagliflozin), which adds to the
More from news
Approximately 8 fully matching, plus 8 partially matching documents found.
There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... From among its product pipeline Smith picks prostate cancer drug orteronel (TAK-700),
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.